Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 4
2(50.0%)
4Total
Phase 1(2)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04995835Phase 1Completed

Cefiderocol PK in Patients on ECMO

Role: lead

NCT04493151Phase 1Completed

Imipenem/Cilastatin/Relebactam PK in ECMO

Role: lead

NCT02421120Phase 4Completed

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

Role: lead

NCT03172793Phase 4Completed

Telavancin Pharmacokinetics in Cystic Fibrosis Patients

Role: lead

All 4 trials loaded